Kaplan-Meier curves for overall survival (A) and progression-free survival (B) of treatment-naïve and pretreated patients with metastatic ocular melanoma who received ipilimumab 3 mg/kg.
figure
posted on 2015-03-11, 02:55 authored by Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G. Griewank, Michael Fluck, Bastian Schilling, Dirk SchadendorfKaplan-Meier curves for overall survival (A) and progression-free survival (B) of treatment-naïve and pretreated patients with metastatic ocular melanoma who received ipilimumab 3 mg/kg.
History
Usage metrics
Categories
Keywords
Metastatic Uveal Melanoma PurposeUpphase III trialsmetastatic UMdisease control rateimmunomodulating agent ipilimumabosctcRECIST 1.1 criteriaNational Cancer Institute Common Toxicity Criteriacutaneous metastatic melanomamulticenter phase II studyDermatologic Cooperative Oncology Groupaenct3 week intervals
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC